The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells

• Những tác giả chính: Alessandra Affinito (Tác giả), Cristina Quintavalle (Tác giả), Carla Lucia Esposito (Tác giả), Giuseppina Roscigno (Tác giả), Claudia Vilardo (Tác giả), Silvia Nuzzo (Tác giả), Lucia Ricci-Vitiani (Tác giả), Gabriele De Luca (Tác giả), Roberto Pallini (Tác giả), Anna S. Kichkailo (Tác giả), Ivan N. Lapin (Tác giả), Vittorio de Franciscis (Tác giả), Gerolama Condorelli (Tác giả)
• Định dạng: Sách
• Được phát hành: Elsevier, 2019-12-01T00:00:00Z.
• Những chủ đề: article
• Truy cập trực tuyến: Connect to this object online.
• Notes: 2162-2531; 10.1016/j.omtn.2019.08.015
• Keywords: Therapeutics. Pharmacology; RM1-950
• Source: Molecular Therapy: Nucleic Acids, Vol 18, Iss , Pp 99-109 (2019)

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Despite progress in surgical and medical neuro-oncology, prognosis for GBM patients remains dismal, with a median survival of only 14-15 months. The modest benefit of conventional therapies is due to the presence of GBM stem cells (GSCs) that cause tumor relapse and chemoresistance and, therefore, that play a key role in GBM aggressiveness and recurrence. So far, strategies to identify and target GSCs have been unsuccessful. Thus, the development of an approach for GSC detection and targeting would be fundamental for improving the survival of GBM patients. Here, using the cell-systematic evolution of ligand by exponential (SELEX) methodology on human primary GSCs, we generated and characterized RNA aptamers that selectively bind GSCs versus undifferentiated GBM cells. We found that the shortened version of the aptamer 40L, which we have called A40s, costained with CD133-labeled cells in human GBM tissue, suggestive of an ability to specifically recognize GSCs in fixed human tissues. Of note, both 40L and A40s were rapidly internalized by cells, allowing for the delivery of the microRNA miR-34c and the anti-microRNA anti-miR-10b, demonstrating that these aptamers can serve as selective vehicles for therapeutics. In conclusion, the aptamers 40L and A40s can selectively target GSCs. Given the crucial role of GSCs in GBM recurrence and therapy resistance, these aptamers represent innovative drug delivery candidates with a great potential in the treatment of GBM. Keywords: aptamer, cancer stem cell, glioblastoma, microRNA, delivery